DMARD and Biologic Therapy

Disease-modifying antirheumatic drugs (DMARDs) are the therapeutic backbone of the inflammatory arthropathies: unlike symptomatic treatments, they aim to suppress the underlying inflammatory process and slow or prevent joint damage. The class spans conventional synthetic agents such as methotrexate, biologic agents that target specific cytokines or immune cells, and targeted synthetic small molecules such as JAK inhibitors.

Definition

DMARD and biologic therapy refers to the classes of agents that modify the course of inflammatory arthritis by suppressing immune-mediated joint inflammation, comprising conventional synthetic DMARDs, biologic DMARDs directed at specific molecular or cellular targets, and targeted synthetic DMARDs.

Scope

This topic introduces the major DMARD categories, the biological rationale that connects them to disease mechanisms, and the strategic principles, treat-to-target and step-up therapy, that govern their use across the inflammatory arthropathies. It describes therapeutic classes and frameworks at a conceptual, population level and deliberately contains no dosing or individualised treatment recommendations.

Core questions

• How do DMARDs differ from symptomatic anti-inflammatory treatments?
• What distinguishes conventional synthetic, biologic, and targeted synthetic DMARDs?
• How do treat-to-target and step-up strategies organise the use of these therapies?

Key concepts

• Conventional synthetic DMARDs (e.g. methotrexate)
• Biologic DMARDs (TNF, IL-6, B-cell, T-cell targeted)
• Targeted synthetic DMARDs (JAK inhibitors)
• Anchor drug concept
• Treat-to-target and step-up therapy
• Cytokine pathways as drug targets
• Comorbidity and safety monitoring

Mechanisms

DMARDs act on the immune mechanisms that drive inflammatory arthritis rather than only on symptoms. Conventional synthetic agents such as methotrexate broadly dampen immune activation and serve as anchor drugs. Biologic DMARDs neutralise specific mediators or cells identified in disease pathogenesis, for example TNF and IL-6 cytokines, B cells, or T-cell co-stimulation, reflecting the cytokine-centred understanding of these diseases. Targeted synthetic DMARDs such as Janus kinase (JAK) inhibitors block intracellular signalling shared by several cytokines. Because chronic inflammation also raises cardiovascular risk, effective disease control is viewed as part of overall risk management.

Clinical relevance

Understanding the DMARD classes and the strategy behind them clarifies how the inflammatory arthropathies are managed in principle: starting with an anchor conventional synthetic DMARD, measuring disease activity, and escalating to biologic or targeted synthetic agents when a treatment target is not reached. This entry is a conceptual overview of therapeutic categories and strategy; it gives no dosing, no individualised regimens, and is not a basis for personal treatment decisions.

Evidence & guidelines

EULAR and ACR management recommendations define the recognised, evidence-based framework for using conventional synthetic, biologic, and targeted synthetic DMARDs in rheumatoid arthritis and related conditions, structured around treat-to-target. Parallel EULAR recommendations address cardiovascular risk management in inflammatory joint disease, reflecting the systemic impact of these conditions. These documents summarise population-level evidence and recommendations rather than prescribing for individuals.

History

Disease-modifying therapy evolved from early agents like gold and antimalarials to the establishment of methotrexate as the anchor drug of rheumatoid arthritis in the late twentieth century. The arrival of TNF inhibitors in the late 1990s opened the biologic era, followed by agents targeting IL-6, B cells, and T-cell co-stimulation, and most recently by oral targeted synthetic JAK inhibitors, alongside the rise of the treat-to-target strategy that governs how these drugs are deployed.

Debates

How should treatment be escalated and de-escalated once a target is reached?

Guidelines support escalating from conventional synthetic to biologic or targeted synthetic DMARDs when targets are unmet, but the optimal sequencing of biologic classes and the safety of tapering therapy after sustained remission remain active areas of discussion.

Key figures

• Josef Smolen
• Daniel Aletaha
• Iain McInnes
• Robert Landewe

Seminal works

• smolen-2017-eular
• smolen-2015-reappraisal
• mcinnes-2011

Frequently asked questions

What makes a drug 'disease-modifying' rather than just anti-inflammatory?

A disease-modifying antirheumatic drug targets the underlying immune process and can slow or prevent structural joint damage over time, whereas symptomatic anti-inflammatory or analgesic treatments relieve pain and swelling without altering disease progression.

What is the difference between biologic and targeted synthetic DMARDs?

Biologic DMARDs are large protein molecules, such as antibodies, that block specific extracellular cytokines or cells, while targeted synthetic DMARDs are small oral molecules, such as JAK inhibitors, that block intracellular signalling shared by several cytokines.